Niacin

Niacin operates through conversion to the pyridine nucleotide coenzymes NAD+ (nicotinamide adenine dinucleotide) and NADP+ (nicotinamide adenine dinucleotide phosphate), whose reduced forms NADH and NADPH are the two dominant electron carriers of intermediary metabolism. These molecules participate in roughly 400 enzymatic reactions — one of the most broadly used cofactor systems in biology — and their availability regulates carbohydrate, lipid, and amino acid metabolism, oxidative phosphorylation, antioxidant defense, cell signaling, and the expanding family of NAD-consuming enzymes that have become central to aging biology.

The three routes to NAD+. Cells synthesize NAD+ through three interconnecting pathways: (1) de novo synthesis from tryptophan via the kynurenine pathway (tryptophan → N-formylkynurenine → kynurenine → 3-hydroxykynurenine → 3-hydroxyanthranilic acid → quinolinic acid → nicotinic acid mononucleotide → NAD+), requiring eight enzymatic steps and cofactors including vitamin B6 (PLP) at multiple points and iron at IDO/TDO; (2) salvage from nicotinamide (the product of NAD-consuming reactions) via nicotinamide phosphoribosyltransferase (NAMPT) to yield nicotinamide mononucleotide (NMN), then NMN adenylyltransferase (NMNAT) to yield NAD+; (3) Preiss-Handler pathway from nicotinic acid (dietary or pharmacologic) via nicotinic acid phosphoribosyltransferase (NAPRT) to yield nicotinic acid mononucleotide, then amidation and adenylation to NAD+. Nicotinamide riboside (NR) enters via a fourth route — phosphorylation by NR kinases (NRK1, NRK2) to yield NMN, merging into the salvage pathway at that step. The existence of multiple independent pathways means that in most tissues, deficiency of one route can be compensated by upregulation of another.

NAD+/NADH in energy metabolism. The NAD+/NADH couple carries electrons from fuel oxidation (glycolysis, beta-oxidation, TCA cycle) to the electron transport chain for oxidative phosphorylation. NAD+ accepts two electrons and one proton to form NADH at dehydrogenase steps (glyceraldehyde-3-phosphate dehydrogenase, pyruvate dehydrogenase, isocitrate dehydrogenase, α-ketoglutarate dehydrogenase, malate dehydrogenase, and beta-oxidation enzymes); NADH is reoxidized to NAD+ at complex I of the mitochondrial electron transport chain, passing electrons to ubiquinone (see the CoQ10 entry for the downstream electron carrier) and ultimately to oxygen with production of ATP. NADH/NAD+ ratio is a critical metabolic regulator: high NADH/NAD+ (reductive stress) signals fuel abundance and inhibits further substrate oxidation; low NADH/NAD+ (or high NAD+) signals fuel shortage and activates fuel-mobilizing pathways.

NADPH in reductive biosynthesis and antioxidant defense. The NADPH/NADP+ couple carries reducing power for reductive biosynthesis (fatty acid synthesis, cholesterol synthesis, deoxyribonucleotide synthesis) and for antioxidant defense (regeneration of reduced glutathione via glutathione reductase, regeneration of thioredoxin). NADPH is produced primarily by the pentose phosphate pathway (glucose-6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase), the malic enzyme, isocitrate dehydrogenase (cytosolic), and folate-dependent methylenetetrahydrofolate reductase reactions. Compartmentalization of NAD+ (predominantly nuclear and cytoplasmic in oxidized form) and NADPH (predominantly cytoplasmic and mitochondrial in reduced form) allows these pools to carry distinct metabolic signals.

NAD-consuming enzymes: sirtuins, PARPs, CD38, SARM1. Four major enzyme families consume NAD+ non-redox (cleaving NAD+ to nicotinamide plus a reaction product rather than reducing it to NADH), producing nicotinamide that must be recycled via the salvage pathway. (1) Sirtuins (SIRT1-7) are NAD-dependent deacylases removing acetyl, succinyl, malonyl, and other acyl groups from protein lysines; they regulate metabolism, stress responses, circadian rhythm, and chromatin via deacetylation of transcription factors (FOXO, p53, NF-κB), histones, and metabolic enzymes. Sirtuins are the molecular targets of the "calorie restriction mimetics" discussion and of resveratrol-based aging interventions. (2) PARPs (poly-ADP-ribose polymerases, especially PARP1) respond to DNA damage by consuming NAD+ to polymerize ADP-ribose onto target proteins, recruiting DNA repair machinery; excessive PARP activity in chronic DNA damage (aging, oxidative stress) can deplete cellular NAD+. (3) CD38 is a cell-surface NAD-glycohydrolase highly expressed on immune cells and increasingly on aging tissues; CD38 upregulation is a major driver of age-related NAD+ decline. (4) SARM1 is an NAD-consuming enzyme activated by axonal injury; its activation depletes neuronal NAD+ and triggers Wallerian axon degeneration — a mechanism increasingly targeted for peripheral neuropathy and ALS drug development. The competition between redox usage (substrate for dehydrogenases) and non-redox consumption (sirtuins, PARPs, CD38) means that cellular NAD+ availability is a shared metabolic and signaling resource, and the age-related decline in NAD+ has become a central narrative of modern aging biology.

Pharmacologic nicotinic acid effects on lipid metabolism. At pharmacologic doses (1-3 g/day), nicotinic acid produces several lipid effects that are distinct from its NAD+ precursor role. (a) LDL-C reduction of 10-25% through reduced hepatic VLDL production and altered LDL kinetics. (b) HDL-C elevation of 15-35%, the largest of any clinically available agent, through reduced HDL catabolism mediated by inhibition of hepatic holo-HDL receptor. (c) Triglyceride reduction of 20-50% through reduced hepatic VLDL secretion. (d) Lipoprotein(a) reduction of 20-40%, one of the few agents with significant Lp(a) lowering effect. (e) Hepatic apoB reduction. The mechanism involves partial inhibition of hepatic diacylglycerol acyltransferase 2 (DGAT2), reduced fatty acid mobilization from adipose tissue (via GPR109A/HCA2 agonism on adipocytes), and reduced hepatic VLDL secretion. These effects are specific to nicotinic acid and are not produced by nicotinamide — a critical distinction for clinical use.

The flushing mechanism. Nicotinic acid''s characteristic cutaneous flush (face, neck, upper chest warmth and erythema within 15-30 minutes of dosing, lasting 30-60 minutes) is mediated by nicotinic acid binding to GPR109A/HCA2 receptors on epidermal Langerhans cells and keratinocytes, triggering prostaglandin D2 (PGD2) release that acts on DP1 receptors on cutaneous vasculature to produce vasodilation. The laropiprant story — a DP1 antagonist combined with niacin (Tredaptive) to block flushing — proved that the mechanism is correct and that blocking flushing does not rescue clinical outcomes (HPS2-THRIVE showed excess adverse effects including myopathy, GI bleeding, and serious infection, leading to worldwide withdrawal). Aspirin 325 mg 30 minutes before niacin dosing blocks prostaglandin synthesis and reduces flushing — a classical clinical tactic. Tachyphylaxis to flushing develops over weeks of daily nicotinic acid dosing, allowing dose escalation.

Nicotinamide pharmacology. Nicotinamide does not engage GPR109A at physiologic concentrations and therefore does not produce flushing; it also lacks the lipid-lowering effects of nicotinic acid because it does not suppress adipose tissue lipolysis. Nicotinamide is preferred for chemoprevention (ONTRAC skin cancer trial), dermatological use, and NAD+ precursor applications in contexts where flushing would limit compliance.

Nicotinamide riboside kinetics. Oral NR is absorbed intact or hydrolyzed to nicotinamide plus ribose, with NR reaching hepatic and peripheral tissues where NRK1/NRK2 phosphorylate it to NMN, entering the salvage pathway. Human pharmacokinetic studies show that NR 250-1000 mg/day reliably raises whole-blood NAD+ by 40-90% within 1-4 weeks. Whether NR achieves intracellular NAD+ increases that translate to clinically meaningful outcomes — metabolic, cardiovascular, neurological, or aging — remains the central unresolved question of the NR/NMN supplement field.

Niacin (vitamin B3) is an umbrella name for a family of closely related vitamers that share the same ultimate metabolic fate — conversion to the pyridine nucleotide coenzymes NAD+ (nicotinamide adenine dinucleotide) and NADP+ (nicotinamide adenine dinucleotide phosphate) that serve as the central electron carriers of intermediary metabolism and as substrates for an expanding family of NAD-consuming enzymes (sirtuins, PARPs, CD38, SARM1). The principal forms are nicotinic acid (the 3-pyridinecarboxylic acid, the form historically isolated as the anti-pellagra factor and now used primarily as a pharmacologic lipid-modifying agent), nicotinamide (also called niacinamide — the amide form, lacking nicotinic acid''s lipid-lowering and flushing effects, preferred for skin cancer prevention and cosmetic/dermatological use), nicotinamide riboside (NR) (the ribosylated nicotinamide form marketed as Tru Niagen/Niagen and studied as an NAD+ precursor for aging and metabolic health), and nicotinamide mononucleotide (NMN) (discussed in its own NMN entry as a closely-related NAD+ precursor). The three-digit Roman numeral naming — B3 — derives from the historical order of B-vitamin discovery rather than any structural logic. The adult RDA is expressed in Niacin Equivalents (NE) because the body synthesizes niacin endogenously from tryptophan at approximately 60 mg tryptophan yielding 1 mg niacin: 16 mg NE/day for men, 14 mg NE/day for women, 18 mg NE/day in pregnancy, 17 mg NE/day in lactation. The tolerable upper intake level is 35 mg/day for nicotinic acid (set primarily because of flushing at higher intakes), but no UL is established for nicotinamide because it does not produce the flushing effect and has a much wider therapeutic window; pharmacologic nicotinamide doses of 1-3 grams daily are used clinically without substantial toxicity. The deficiency disease, pellagra, is among the most historically important nutritional syndromes of the past two centuries: the disease of the "four Ds" — dermatitis (photosensitive eruption, classically in sun-exposed areas, the "Casal''s necklace" across the neck and upper chest), diarrhea, dementia, and death if untreated — devastated the American South, southern Europe, and parts of Africa during eras of corn-dependent diet without traditional nixtamalization (the alkaline lime treatment of corn practiced by Mesoamerican cultures that liberates bound niacin and dramatically improves bioavailability). Joseph Goldberger''s 1910s-1920s demonstration that pellagra was a dietary disease rather than an infection is a landmark in American public health history ( for historical context). Grain fortification with niacin starting in the 1940s all but eliminated pellagra from the developed world, and frank deficiency today is seen predominantly in chronic alcohol use, isoniazid therapy without B6 repletion (INH inhibits pyridoxal-dependent kynurenine pathway conversion to niacin), carcinoid syndrome (tryptophan diverted into serotonin synthesis), Hartnup disease (SLC6A19 mutations impairing neutral amino acid transport including tryptophan), and severe malabsorption or feeding disorders. The supplement and clinical uses of niacin cluster in several domains. Pharmacologic nicotinic acid for dyslipidemia was a mainstay of lipid-lowering therapy from the 1950s through the 2000s, backed by the original Coronary Drug Project (CDP) showing reduced coronary events in men treated with niacin 3 g/day, and by long-term follow-up from Canner 1986 showing mortality reduction 15 years out— but subsequent combination trials in the statin era (AIM-HIGH 2011 and HPS2-THRIVE 2014) did not show benefit of adding niacin to statin therapy, and modern guidelines have de-emphasized niacin for routine lipid management despite its continued availability (PMID 22085343, 25014686). Nicotinamide for non-melanoma skin cancer chemoprevention is a more recent and strong evidence base — the ONTRAC trial (Chen 2015, PMID 26488693) showed that nicotinamide 500 mg twice daily reduced new basal cell and squamous cell carcinomas by 23% in high-risk patients over 12 months, establishing nicotinamide as a low-cost adjunct in dermatological practice. Nicotinamide for acne, rosacea, bullous pemphigoid has a smaller but positive evidence base at pharmacologic doses (500-1500 mg/day). Topical niacinamide in skincare is among the most widely-used active ingredients in modern cosmetic formulations at 2-10% concentrations, with evidence for reduced hyperpigmentation, improved barrier function, reduced erythema, and modest anti-aging effects. Nicotinamide riboside (NR) as an NAD+ precursor has emerged since Brenner''s 2004 discovery of the NR → NMN → NAD+ salvage pathway (PMID 15137942), with commercial formulations (Niagen, Tru Niagen; ChromaDex) and human trials showing reliable elevation of blood NAD+ and promising but not yet definitive metabolic, cardiovascular, and anti-aging effects (PMID 29599478, 29985198). NMN is discussed in its own NMN entry. High-dose nicotinamide for Alzheimer, Parkinson, and ALS is an active research area given the NAD+ depletion observed in aging brain and the role of SARM1 (an NAD-consuming enzyme) in axonal degeneration — evidence remains preliminary. Niacin for schizophrenia (the megavitamin approach of Hoffer and Osmond in the 1950s) was never confirmed in controlled trials and is historical rather than current practice. No-flush niacin (inositol hexanicotinate) is marketed as a flushing-free alternative but produces lower circulating nicotinic acid and has limited lipid-lowering effect. Slow-release/extended-release nicotinic acid (Niaspan) was developed to reduce flushing and was widely used before the AIM-HIGH/HPS2-THRIVE failures; it remains available. Laropiprant (DP1/PGD2 receptor antagonist) combined with nicotinic acid (Tredaptive) was withdrawn worldwide after HPS2-THRIVE showed excess adverse effects (PMID 25014686). See also the NMN and NAD+ entries for the precursor biology and aging-research context, [Tryptophan] for the amino acid precursor pathway, Vitamin B6 for the kynurenine pathway cofactor partnership, Folate and Vitamin B12 for the broader B-complex, Thiamine for the companion energy-metabolism cofactor story, Alpha-Lipoic Acid for the mitochondrial redox stack, CoQ10 for the electron transport chain partnership, [Resveratrol] for the sirtuin-activator discussion, and Metformin for the AMPK-NAD-sirtuin aging axis. This overview is educational only and is not medical advice — pharmacologic nicotinic acid has specific cardiovascular, hepatic, and glycemic effects that warrant clinician oversight; nicotinamide at typical supplement doses is much more forgiving.

IUPAC Name

Not yet available

CAS Number

Not yet available

Molecular Formula

Not yet available

Molecular Mass

Not yet available

Unlock Dosing Protocols

Free account gets you:

• View beginner, intermediate & advanced protocols
• See weight-based dosing calculations
• Access cycle length & frequency data

2,800+ researchers already in

Unlock Research Data

Free account gets you:

• Browse PubMed study summaries
• See clinical trial phases & results
• Access mechanism of action details

2,800+ researchers already in

Get Niacin Price Drop Alerts

Set a target price and we'll notify you when any vendor drops below it.

Sign in to set alerts

Related Compounds

View All

Data Completeness

50%